Physician profile
Rafael Baez
NPI 1679526826
$5,520.79
in general payments reported to CMS, 2019-2025
28 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $366 · 2021: $1,473 · 2022: $1,716 · 2023: $594 · 2024: $272 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,392.12 | 2020-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $772.93 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Abbott Laboratories | $596.24 | 2019-2020 | |
| Exact Sciences Corporation | $343.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $242.28 | 2019-2024 | |
| Glaxosmithkline, LLC. | $150.30 | 2020-2023 | Shingrix |
| Bard Peripheral Vascular, INC. | $138.94 | 2019 | |
| Lilly USA, LLC | $124.20 | 2019-2025 | Jardiance, Emgality |
| Abbvie INC. | $106.62 | 2021-2024 | Qulipta |
| Amgen INC. | $105.66 | 2023-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $63.44 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $56.38 | 2023 | Lyvispah |
| Hologic Sales and Service, LLC | $56.29 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Vifor Pharma, INC. | $43.97 | 2021-2023 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.37 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.30 | 2022 | |
| Astellas Pharma US INC | $32.28 | 2025 | Veozah |
| Calliditas Therapeutics US INC. | $26.60 | 2023 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $26.20 | 2025 | |
| Angiodynamics, INC. | $24.19 | 2019 | |
| Zyla Life Sciences, INC. | $23.70 | 2019 | |
| Opko Pharmaceuticals, LLC | $22.29 | 2021 | |
| Genentech USA, INC. | $21.77 | 2019 | |
| Novo Nordisk INC | $17.93 | 2023 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $15.46 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $14.29 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.18 | 2024 | Terlivaz |
| Orexo US, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Baez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.